美国 · SEC FORM 4
BIOCRYST PHARMACEUTICALS INC
BCRX · Nasdaq · CIK 0000882796 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
22 同一窗口内观察到的 Form 4 交易行
2 sales · 20 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-05-30 · LEVIN ALAN G.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -4.9%
- 3M
- -13.7%
- 6M
- -15.8%
- 12M
- +24.9%
波动率与流动性
- 波动率
- 50.3%
- Beta
- —
- 平均每日成交额
- USD 33.0M
估值
- 市值
- USD 2.0B
- P/E
- 7.8×
基本面
- 利润率
- 30.2%
- ROE
- —
- 细分行业
- Drug Manufacturers—Specialty & Generic
市场数据
价格数据截至：2026-10-15 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, P/E, 利润率 · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 27,494,721
- 上期报告
- 34,868,460
- 日均成交量
- 5,955,260
- 回补天数
- 4.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-05-30 | LEVIN ALAN G | 买入 (P) | Common Stock | 7,861 | USD 6.36 | USD 49,996 | SEC 申报 ↗ |
| 2024-05-24 | ASELAGE STEVE | 买入 (P) | Common Stock | 2,500 | USD 6.40 | USD 16,000 | SEC 申报 ↗ |
| 2024-05-20 | MILANO VINCENT | 买入 (P) | Common Stock | 15,000 | USD 6.25 | USD 93,750 | SEC 申报 ↗ |
| 2024-05-20 | Hutson Nancy J | 买入 (P) | Common Stock | 5,000 | USD 6.38 | USD 31,900 | SEC 申报 ↗ |
| 2024-05-14 | Thackray Helen M. | 买入 (P) | Common Stock | 30,000 | USD 5.86 | USD 175,800 | SEC 申报 ↗ |
| 2024-05-14 | Doyle Anthony | 买入 (P) | Common Stock | 36,300 | USD 5.57 | USD 202,191 | SEC 申报 ↗ |
| 2024-05-13 | Stonehouse Jon P | 买入 (P) | Common Stock | 30,000 | USD 5.55 | USD 166,500 | SEC 申报 ↗ |
| 2024-05-13 | Gayer Charles K | 买入 (P) | Common Stock | 30,000 | USD 5.47 | USD 164,100 | SEC 申报 ↗ |
| 2024-05-13 | Galson Steven K | 买入 (P) | Common Stock | 21,940 | USD 5.49 | USD 120,451 | SEC 申报 ↗ |
| 2024-05-13 | Barnes Alane P | 买入 (P) | Common Stock | 5,000 | USD 5.53 | USD 27,650 | SEC 申报 ↗ |
| 2021-11-24 | MILANO VINCENT | 买入 (P) | Common Stock | 7,500 | USD 12.19 | USD 91,425 | SEC 申报 ↗ |
| 2021-11-23 | Doyle Anthony | 买入 (P) | Common Stock | 35,258 | USD 12.48 | USD 440,020 | SEC 申报 ↗ |
| 2020-08-11 | Doyle Anthony | 买入 (P) | Common Stock | 54,000 | USD 4.08 | USD 220,320 | SEC 申报 ↗ |
Form 4 申报证据
60 transaction lines in the latest 365-day window; 332 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Stonehouse Jon P | 奖励／授予 (A) | Common Stock | 644 | USD 9.70 | USD 6,247 | SEC 申报 ↗ |
| 2026-08-31 | Milne Jill C. | 奖励／授予 (A) | Common Stock | 1,288 | USD 9.70 | USD 12,494 | SEC 申报 ↗ |
| 2026-08-31 | McKee Amy E | 奖励／授予 (A) | Common Stock | 644 | USD 9.70 | USD 6,247 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Stonehouse Jon P | 奖励／授予 (A) | Common Stock | 644 | USD 9.70 | USD 6,247 | SEC 申报 ↗ |
| 2026-08-31 | Milne Jill C. | 奖励／授予 (A) | Common Stock | 1,288 | USD 9.70 | USD 12,494 | SEC 申报 ↗ |
| 2026-08-31 | McKee Amy E | 奖励／授予 (A) | Common Stock | 644 | USD 9.70 | USD 6,247 | SEC 申报 ↗ |
| 2026-08-31 | MILANO VINCENT | 奖励／授予 (A) | Common Stock | 1,159 | USD 9.70 | USD 11,242 | SEC 申报 ↗ |
| 2026-08-31 | Frank Steven | 奖励／授予 (A) | Common Stock | 1,288 | USD 9.70 | USD 12,494 | SEC 申报 ↗ |
| 2026-06-11 | Stonehouse Jon P | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | SANDERS MACHELLE | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | Milne Jill C. | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | McKee Amy E | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | MILANO VINCENT | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | LEVIN ALAN G | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | HEGGIE THERESA | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | Galson Steven K | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | Frank Steven | 奖励／授予 (A) | Common Stock | 15,294 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-29 | Stonehouse Jon P | 奖励／授予 (A) | Common Stock | 631 | USD 8.91 | USD 5,622 | SEC 申报 ↗ |
| 2026-05-29 | Milne Jill C. | 奖励／授予 (A) | Common Stock | 1,262 | USD 8.91 | USD 11,244 | SEC 申报 ↗ |
| 2026-05-29 | McKee Amy E | 奖励／授予 (A) | Common Stock | 631 | USD 8.91 | USD 5,622 | SEC 申报 ↗ |
| 2026-05-29 | MILANO VINCENT | 奖励／授予 (A) | Common Stock | 1,122 | USD 8.91 | USD 9,997 | SEC 申报 ↗ |
| 2026-05-29 | Frank Steven | 奖励／授予 (A) | Common Stock | 1,262 | USD 8.91 | USD 11,244 | SEC 申报 ↗ |
| 2026-05-18 | McKee Amy E | 卖出 (S) | Common Stock | 11,180 | USD 8.97 | USD 100,285 | SEC 申报 ↗ |
| 2026-05-13 | Barnes Alane P | 卖出 (S) | Common Stock | 62,500 | USD 9.54 | USD 596,250 | SEC 申报 ↗ |
| 2026-05-13 | Barnes Alane P | 期权行权／转换 (M) | Common Stock | 62,500 | USD 5.04 | USD 315,000 | SEC 申报 ↗ |
| 2026-04-06 | Menon Sandeep | 奖励／授予 (A) | Common Stock | 205,150 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-20 | HEGGIE THERESA | 卖出 (S) | Common Stock | 49,933 | USD 10.11 | USD 504,823 | SEC 申报 ↗ |
| 2026-03-20 | HEGGIE THERESA | 期权行权／转换 (M) | Common Stock | 49,933 | USD 6.30 | USD 314,578 | SEC 申报 ↗ |
| 2026-03-16 | Barnes Alane P | 卖出 (S) | Common Stock | 150,000 | USD 9.15 | USD 1,372,500 | SEC 申报 ↗ |
| 2026-03-16 | Barnes Alane P | 期权行权／转换 (M) | Common Stock | 150,000 | USD 5.51 | USD 826,500 | SEC 申报 ↗ |
| 2026-03-02 | Stonehouse Jon P | 期权行权／转换 (M) | Common Stock | 305,995 | USD 3.22 | USD 985,304 | SEC 申报 ↗ |
| 2026-03-02 | Stonehouse Jon P | D (D) | Common Stock | 305,995 | USD 8.64 | USD 2,643,797 | SEC 申报 ↗ |
| 2026-02-27 | Stonehouse Jon P | 奖励／授予 (A) | Common Stock | 421 | USD 8.75 | USD 3,684 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | BCRX |
| CIK | 0000882796 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 332 transaction lines from 2020-03-01 to 2026-08-31 13 P purchase lines · 54 S sale lines · 265 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.